Companion Diagnostics: Predicting if Cancer Drugs Will Work Before Treatment
02 October 2007
New biomarker development, based on changes in kinase activity, is at the root of PamGene's drive towards making 'companion diagnostics' a reality. Using these new biomarkers, PamGene's technology platform can measure the effect of a drug on kinase activity in the patient's own tissue (a biopsy) prior to treatment.
In other words, strong hints about the likelihood of a cancer drug's effectiveness in that patient can be obtained before initiating treatment. This has important implications for patient treatment, clinical trials, and for the agencies that finance drug therapy.
